News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
750,861 Results
Type
Article (64293)
Company Profile (295)
Press Release (686273)
Multimedia
Podcasts (60)
Webinars (12)
Section
Business (212621)
Career Advice (2382)
Deals (36326)
Drug Delivery (101)
Drug Development (84553)
Employer Resources (178)
FDA (16604)
Job Trends (15544)
News (359209)
Policy (33937)
Tag
Academia (2921)
Academic (1)
Accelerated approval (5)
Adcomms (22)
Allergies (88)
Alliances (52849)
ALS (93)
Alzheimer's disease (1457)
Antibody-drug conjugate (ADC) (132)
Approvals (16599)
Artificial intelligence (272)
Autoimmune disease (23)
Automation (16)
Bankruptcy (366)
Best Places to Work (11979)
BIOSECURE Act (20)
Biosimilars (106)
Biotechnology (200)
Bladder cancer (79)
Brain cancer (29)
Breast cancer (285)
Cancer (2325)
Cardiovascular disease (181)
Career advice (1988)
Career pathing (32)
CAR-T (158)
Cell therapy (445)
Cervical cancer (20)
Clinical research (68182)
Collaboration (877)
Company closure (1)
Compensation (534)
Complete response letters (20)
COVID-19 (2779)
CRISPR (43)
C-suite (257)
Cystic fibrosis (104)
Data (2238)
Decentralized trials (2)
Denatured (22)
Depression (48)
Diabetes (276)
Diagnostics (6660)
Digital health (20)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (127)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87799)
Editorial (44)
Employer branding (22)
Employer resources (153)
Events (116910)
Executive appointments (751)
FDA (17888)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (784)
Gene editing (110)
Generative AI (24)
Gene therapy (320)
GLP-1 (747)
Government (4650)
Grass and pollen (5)
Guidances (67)
Healthcare (19614)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (121)
Indications (30)
Infectious disease (2929)
Inflammatory bowel disease (141)
Inflation Reduction Act (8)
Influenza (54)
Intellectual property (97)
Interviews (404)
IPO (16789)
IRA (44)
Job creations (3993)
Job search strategy (1690)
Kidney cancer (10)
Labor market (38)
Layoffs (497)
Leadership (19)
Legal (8196)
Liver cancer (77)
Lung cancer (328)
Lymphoma (155)
Machine learning (7)
Management (61)
Manufacturing (318)
MASH (70)
Medical device (13671)
Medtech (13676)
Mergers & acquisitions (20078)
Metabolic disorders (707)
Multiple sclerosis (84)
NASH (16)
Neurodegenerative disease (95)
Neuropsychiatric disorders (27)
Neuroscience (2016)
NextGen: Class of 2025 (6833)
Non-profit (4848)
Now hiring (39)
Obesity (374)
Opinion (226)
Ovarian cancer (76)
Pain (91)
Pancreatic cancer (85)
Parkinson's disease (152)
Partnered (22)
Patents (237)
Patient recruitment (113)
Peanut (48)
People (60123)
Pharmaceutical (69)
Pharmacy benefit managers (18)
Phase I (21287)
Phase II (29903)
Phase III (22205)
Pipeline (1218)
Policy (150)
Postmarket research (2938)
Preclinical (9598)
Press Release (70)
Prostate cancer (109)
Psychedelics (33)
Radiopharmaceuticals (259)
Rare diseases (393)
Real estate (6474)
Recruiting (67)
Regulatory (23228)
Reports (46)
Research institute (2627)
Resumes & cover letters (393)
Rett syndrome (5)
RNA editing (5)
RSV (45)
Schizophrenia (73)
Series A (135)
Series B (85)
Service/supplier (17)
Sickle cell disease (55)
Special edition (15)
Spinal muscular atrophy (155)
Sponsored (31)
Startups (3830)
State (2)
Stomach cancer (14)
Supply chain (70)
Tariffs (43)
The Weekly (36)
Vaccines (744)
Venture capitalists (41)
Weight loss (247)
Women's health (37)
Worklife (18)
Date
Today (141)
Last 7 days (922)
Last 30 days (2676)
Last 365 days (33599)
2025 (10997)
2024 (36161)
2023 (41107)
2022 (52384)
2021 (57023)
2020 (55704)
2019 (48519)
2018 (36606)
2017 (33843)
2016 (33881)
2015 (40476)
2014 (34377)
2013 (30567)
2012 (32171)
2011 (32528)
2010 (31142)
Location
Africa (881)
Alabama (55)
Alaska (7)
Arizona (246)
Arkansas (13)
Asia (41646)
Australia (7280)
California (6228)
Canada (2030)
China (541)
Colorado (269)
Connecticut (279)
Delaware (151)
Europe (93631)
Florida (919)
Georgia (211)
Idaho (58)
Illinois (559)
India (27)
Indiana (311)
Iowa (11)
Japan (166)
Kansas (107)
Kentucky (25)
Louisiana (10)
Maine (62)
Maryland (917)
Massachusetts (4658)
Michigan (220)
Minnesota (403)
Mississippi (2)
Missouri (83)
Montana (30)
Nebraska (25)
Nevada (64)
New Hampshire (65)
New Jersey (1751)
New Mexico (31)
New York (1777)
North Carolina (1030)
North Dakota (9)
Northern California (2709)
Ohio (210)
Oklahoma (14)
Oregon (36)
Pennsylvania (1388)
Puerto Rico (12)
Rhode Island (33)
South America (1245)
South Carolina (24)
South Dakota (1)
Southern California (2338)
Tennessee (103)
Texas (928)
United States (23603)
Utah (186)
Virginia (151)
Washington D.C. (65)
Washington State (564)
West Virginia (3)
Wisconsin (57)
750,861 Results for "albany molecular research inc amri".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SK Life Science Labs Announces the Publication in Nature Communications of its Breakthrough Research on Molecular Glue Discovery to Advance Cancer Immunotherapy
May 2, 2025
·
4 min read
Collaboration
Lilly Hops On Hot Molecular Glue Train With $1.2B+ Magnet Deal
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and Novartis.
February 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence’s Management Team as Chief Operating Officer
March 26, 2025
·
4 min read
Press Releases
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
April 29, 2025
·
8 min read
Press Releases
Children’s Hospital of Philadelphia Researchers Lead First Study to Identify Molecular Basis of Food Allergy
February 5, 2025
·
4 min read
Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com
Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com.
June 6, 2024
·
2 min read
Press Releases
Angelman Syndrome Market Size to Reach USD 172.8 Million by 2035, Impelled by Advancements in Genetic and Molecular Research
January 23, 2025
·
10 min read
Lone Star Bio
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. today provided an update on its clinical-stage programs.
June 3, 2024
·
7 min read
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
·
6 min read
·
Kate Goodwin
Press Releases
Meridian Bioscience Introduces New Enzyme Stabilization Services for Molecular Diagnostics
April 23, 2025
·
4 min read
1 of 75,087
Next
